Home » Stocks » Amryt Pharma

Amryt Pharma PLC (AMYT)

Stock Price: $11.61 USD 0.27 (2.38%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.79B
Revenue (ttm) 98.16M
Net Income (ttm) n/a
Shares Out 31.70M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $11.61
Previous Close $11.34
Change ($) 0.27
Change (%) 2.38%
Day's Open 11.39
Day's Range 11.30 - 11.95
Day's Volume 6,998
52-Week Range 10.06 - 12.49

More Stats

Market Cap 1.79B
Enterprise Value 1.91B
Earnings Date (est) Apr 21, 2021
Ex-Dividend Date n/a
Shares Outstanding 31.70M
Float 14.53M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 934
Short Ratio 0.17
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 18.27
PB Ratio 3.49
Revenue 98.16M
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash -116.18M
Net Cash / Share -0.75
Gross Margin 26.99%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(210.59% upside)
Current: $11.61
Target: 36.06
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth240.01%-
Gross Profit16.1210.83
Operating Income-53.75-18.04
Net Income-65.54-30.49
Earnings Per Share-4.30-3.35
Operating Cash Flow-37.50-15.45
Capital Expenditures-0.65-0.24
Free Cash Flow-38.15-15.69
Cash & Equivalents67.2311.23
Total Debt17819.01
Net Cash / Debt-111-7.79
Book Value129-3.70
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Amryt Pharma PLC
Country Ireland
Employees 169
CEO Joseph Wiley

Stock Information

Ticker Symbol AMYT
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: AMYT


Amryt Pharma plc, a biopharmaceutical company, develops and commercializes various therapeutics to treat patients suffering from serious and life-threatening rare diseases. Its commercial products include Lojuxta/Juxtapid, a prescription medicine used along with diet and other lipid-lowering treatments, including low-density lipoprotein (LDL) apheresis in adults with homozygous familial hypercholesterolaemia; Myalept/Myalepta for injection, a leptin replacement therapy used with a doctor-recommended diet to treat problems caused by not having enough leptin in the body; and a range of derma-cosmetic products. The company's development candidates comprise Oleogel-S10 (AP101) for the treatment of epidermolysis bullosa in young children and adults; and AP103, a pre-clinical gene-therapy platform technology that offers a treatment for patients with recessive dystrophic epidermolysis bullosa. Amryt Pharma plc was incorporated in 2019 and is based in London, the United Kingdom.